Neogap is a clinical-stage company developing a personalised, tumour-targeted T-cell therapy using PIOR® (ML-driven neoantigen selection) and EpiTCer® (selective activation of tumour-reactive T cells). Our ongoing Phase I/IIa CRC trial shows favourable safety, immune activation, and long-term persistence of tumour-specific T cells. With ~97,000 eligible patients annually in the US/EU (€1.4–1.9B potential), we are seeking partners to accelerate development, expand into the US, and advance next-generation IO opportunities.